Advice

Following a re-submission

anidulafungin (Ecalta®) is accepted for restricted use within NHS Scotland for the treatment of invasive candidiasis in adult non-neutropenic patients.

Anidulafungin has been shown to be at least as effective as an alternative antifungal in a study of patients, the majority of whom had candidaemia. Its use is restricted to patients who are unable to tolerate fluconazole or have invasive candidiasis that is resistant to fluconazole.

Download detailed advice96KB (PDF)

Download

Medicine details

Medicine name:
anidulafungin (Ecalta)
SMC ID:
465/08
Indication:
Invasive candidiasis in adult non-neutropenic patients
Pharmaceutical company
Pfizer Ltd
BNF chapter
Infections
Submission type
Resubmission
Status
Restricted
Date advice published:
10 November 2008